EVMN
Evommune, Inc.
NYSEUSDEQUITY
DELAYED
Last price
13.74
▲ 0.17 (1.25%)
MARKET · —
Price
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
13.57
Prev close
13.57
Day high
14.25
Day low
13.72
Volume
275.08K
Market cap
—
P/E (TTM)
—
52W range
10.47 – 33.20
Trailing performance
Returnvs SPY
1W
-4.30%
-2.9%
1M
+23.85%
+20.1%
3M
-40.47%
-43.6%
6M
-50.48%
-61.5%
YTD
-18.11%
-30.4%
1Y
—
-20.0%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on EVMN open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Total revenue | $13.00M | — | — |
| Operating revenue | $13.00M | — | — |
| Research & development | $74.04M | — | — |
| Selling, general & admin | $20.03M | — | — |
| Total operating expense | $94.07M | — | — |
| Operating income | -$81.07M | — | — |
| Net interest income | $3.32M | — | — |
| Pre-tax income | -$68.87M | — | — |
| Net income | -$68.87M | — | — |
| Net income to common | -$68.87M | — | — |
| Basic EPS | -11.22 | -4.27 | -162.8% |
| Diluted EPS | -11.22 | -4.27 | -162.8% |
| EBIT | -$81.07M | — | — |
| EBITDA | -$79.68M | — | — |
| Basic shares | 6.14M | 16.00M | -61.6% |
| Diluted shares | 6.14M | 16.00M | -61.6% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Cash & equivalents | $44.06M | — | — |
| Cash & short-term investments | $149.20M | — | — |
| Total current assets | $153.48M | — | — |
| Property, plant & equipment | $2.46M | — | — |
| Total assets | $224.95M | — | — |
| Total current liabilities | $17.91M | — | — |
| Total debt | $1.71M | $1.02M | +67.6% |
| Total liabilities | $19.38M | — | — |
| Retained earnings | -$221.09M | — | — |
| Shareholder equity | $205.57M | — | — |
| Working capital | $135.57M | — | — |
| Net tangible assets | $205.57M | — | — |
| Shares issued | 31.52M | — | — |
| Line item | 2025 | YoY |
|---|---|---|
| Net income | -$68.87M | |
| Depreciation & amortisation | $1.39M | |
| Stock-based compensation | $5.86M | |
| Change in working capital | -$4.12M | |
| Operating cash flow | -$76.44M | |
| Capital expenditure | -$235.00K | |
| Investing cash flow | -$115.31M | |
| Financing cash flow | $220.76M | |
| Free cash flow | -$76.68M | |
| End cash position | $45.48M |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $10.00M | — | $0 | — |
| Operating revenue | $0 | $0 | $0 | $10.00M | — | $0 | — |
| Research & development | $26.41M | $17.32M | $20.40M | $19.64M | — | $17.83M | +52.5% |
| Selling, general & admin | $8.48M | $6.63M | $9.31M | $3.69M | — | $3.62M | +27.9% |
| Total operating expense | $34.90M | $23.95M | $29.72M | $23.33M | — | $21.45M | +45.7% |
| Operating income | -$34.90M | -$23.95M | -$29.72M | -$13.33M | — | -$21.45M | -45.7% |
| Net interest income | $2.65M | $2.28M | $1.44M | $862.00K | $403.00K | — | +16.1% |
| Pre-tax income | -$32.25M | -$21.67M | -$28.27M | -$12.47M | — | -$20.73M | -48.8% |
| Net income | -$32.25M | -$21.67M | -$28.27M | -$12.47M | — | -$20.73M | -48.8% |
| Net income to common | -$32.25M | -$21.67M | -$28.27M | -$12.47M | — | -$22.23M | -48.8% |
| Basic EPS | -0.89 | -0.64 | -1.43 | -0.41 | -0.45 | — | -39.1% |
| Diluted EPS | -0.89 | -0.64 | -1.43 | -0.41 | -0.45 | — | -39.1% |
| EBIT | -$34.90M | -$23.95M | -$29.72M | -$13.33M | — | -$21.45M | -45.7% |
| EBITDA | -$34.34M | -$23.61M | -$29.39M | -$13.02M | — | -$21.09M | -45.5% |
| Basic shares | 36.14M | 33.67M | 19.78M | 30.08M | 30.08M | — | +7.3% |
| Diluted shares | 36.14M | 33.67M | 19.78M | 30.08M | 30.08M | — | +7.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $60.03M | $48.32M | $44.06M | $26.82M | $16.25M | +24.2% |
| Cash & short-term investments | $200.79M | $211.46M | $149.20M | $76.06M | $72.04M | -5.0% |
| Total current assets | $204.25M | $215.85M | $153.48M | $81.94M | $73.99M | -5.4% |
| Property, plant & equipment | $9.22M | $9.57M | $2.46M | $1.13M | $1.80M | -3.7% |
| Total assets | $301.95M | $322.45M | $224.95M | $84.54M | $76.06M | -6.4% |
| Total current liabilities | $17.49M | $10.60M | $17.91M | $10.42M | $27.98M | +64.9% |
| Total debt | $8.11M | $8.55M | $1.71M | $160.00K | $1.02M | -5.1% |
| Total liabilities | $24.36M | $17.90M | $19.38M | $267.68M | $220.29M | +36.1% |
| Retained earnings | -$275.01M | -$242.76M | -$221.09M | -$192.82M | -$152.22M | -13.3% |
| Shareholder equity | $277.59M | $304.56M | $205.57M | -$183.14M | -$144.24M | -8.9% |
| Working capital | $186.76M | $205.25M | $135.57M | $71.53M | $46.01M | -9.0% |
| Net tangible assets | $277.59M | $304.56M | $205.57M | -$183.14M | -$144.24M | -8.9% |
| Shares issued | 36.02M | 36.02M | 31.52M | 30.08M | 30.08M | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$32.25M | -$21.67M | -$28.27M | -$12.47M | -$20.73M | -48.8% |
| Depreciation & amortisation | $552.00K | $349.00K | $326.00K | $311.00K | $360.00K | +58.2% |
| Stock-based compensation | $4.60M | $3.45M | $4.20M | $560.00K | $494.00K | +33.1% |
| Change in working capital | $7.54M | -$8.84M | $7.64M | $2.48M | $1.81M | +185.2% |
| Operating cash flow | -$20.32M | -$27.50M | -$16.70M | -$9.63M | -$18.51M | +26.1% |
| Capital expenditure | -$183.00K | -$83.00K | -$104.00K | — | — | -120.5% |
| Investing cash flow | $31.29M | -$85.36M | -$122.90M | -$23.91M | -$33.08M | +136.7% |
| Financing cash flow | $532.00K | $117.11M | $156.85M | -$274.00K | $49.70M | -99.5% |
| Free cash flow | -$20.50M | -$27.59M | -$16.80M | -$9.77M | -$18.51M | +25.7% |
| End cash position | $61.24M | $49.73M | $45.48M | $28.23M | $16.46M | +23.1% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
14.22
-3.37% from price
SMA 20
13.19
+6.32% from price
SMA 50
14.90
-5.89% from price
SMA 100
19.37
-29.06% from price
SMA 200
—
—
EMA 12
13.89
-1.11% from price
EMA 26
13.83
-0.64% from price
EMA 50
15.12
-9.11% from price
RSI (14)
51.2
Neutral
MACD (12,26,9)
0.07
Hist 0.26
ATR (14)
0.84
6.01% of price
Realised vol 30D
72.6%
Annualised
Bollinger upper
15.79
20, 2σ
Bollinger lower
10.59
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.00
Less volatile than market
Correlation to SPY
0.11
Largely independent
Realised vol 30D
72.6%
Annualised
Market vol 1Y
13.3%
SPY, annualised
Max drawdown 1Y
-65.0%
Peak to trough
Max drawdown 5Y
-65.0%
Peak to trough
ATR 14
0.84
6.01% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
RBC Adjusts PT on Evommune to $29 From $30, Maintains Outperform Speculative Risk Rating
MT Newswires · 16d ago
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
Business Wire · 16d ago
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
Business Wire · 24d ago
EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal
Zacks · 53d ago
Top Midday Decliners
MT Newswires · 54d ago
Evommune terminates oral drug’s development in CSU
Clinical Trials Arena · 54d ago
Evommune Shares Slide After Phase 2b CSU Trial Misses Main Goal (EVMN)
InvestorsHub · 55d ago
Evommune's Trial of EVO756 Misses Primary Endpoint; Shares Tumble Pre-Bell
MT Newswires · 55d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.